The HNO donor Angeli's salt offers potential haemodynamic advantages over NO• or dobutamine in ischaemia-reperfusion injury in the rat heart ex vivo.

In contrast to the β1-adreneoceptor (β1-AR) agonist dobutamine and the NO donor diethylamine NONOate (DEA/NO), the vasodilation properties of the nitroxyl (HNO) donor Angeli’s salt were preserved after ischaemia–reperfusion (I–R) injury. Although I–R injury blunted the inotropic effects of both Angeli’s salt and dobutamine, the HNO donor did not increase heart rate (HR). Improved recovery of left ventricular function (LVF) and reduced incidence of arrhythmias was also observed. HNO donors may thus offer haemodynamic advantages over existing pharmacotherapy in acute heart failure. AC, adenylyl cyclase; O2−, superoxide; ONOO−, peroxynitrite; PKA, protein kinase A, PKG, protein kinase G; sGC, soluble guanylyl cyclase, SH, thiol. Blue and red text represent beneficial and detrimental effects, respectively. Grey arrows indicate more modest effects than black arrows.